Compare AMN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMN | TSHA |
|---|---|---|
| Founded | 1985 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2001 | 2020 |
| Metric | AMN | TSHA |
|---|---|---|
| Price | $35.74 | $3.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $44.79 | $13.00 |
| AVG Volume (30 Days) | 787.0K | ★ 2.5M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.58 | 5.56 |
| EPS | ★ 2.93 | N/A |
| Revenue | ★ $1,988,454,000.00 | $9,773,000.00 |
| Revenue This Year | $25.69 | N/A |
| Revenue Next Year | N/A | $6,389.64 |
| P/E Ratio | $11.73 | ★ N/A |
| Revenue Growth | 4.53 | ★ 17.28 |
| 52 Week Low | $14.97 | $3.46 |
| 52 Week High | $49.62 | $7.30 |
| Indicator | AMN | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 34.29 |
| Support Level | $34.96 | $3.46 |
| Resistance Level | $36.36 | $4.57 |
| Average True Range (ATR) | 2.43 | 0.28 |
| MACD | -0.99 | -0.03 |
| Stochastic Oscillator | 11.94 | 11.29 |
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. A majority of its revenue is generated from the Nurse and Allied Solutions segment, which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.